NCT04166734 2026-02-04MESO-PRIMERoyal Marsden NHS Foundation TrustPhase 1 Terminated5 enrolled 13 charts
NCT05070247 2026-01-22A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTakedaPhase 1/2 Terminated61 enrolled 29 charts
NCT02903914 2025-08-05Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsIncyte CorporationPhase 1 Completed260 enrolled 52 charts
NCT02784171 2024-12-10Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCanadian Cancer Trials GroupPhase 2/3 Completed520 enrolled 16 charts 1 FDA
NCT03644550 2021-12-02Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaNational Institutes of Health Clinical Center (CC)Phase 2 Terminated18 enrolled 15 charts
NCT03277352 2021-07-22INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Terminated10 enrolled 14 charts